BioNTech and Pfizer's endeavour to create a combination flu and COVID-19 vaccine exhibited mixed results in late-stage trials, hitting only 1 of 2 endpoints. Moreover, the BioNTech-Pfizer alliance has been facing mounting legal issues, including a lawsuit by the University of Pennsylvania for full royalty payments and GlaxoSmithKline suing over previous COVID-19 vaccine technology. However, the firm sees a silver lining with its investigational mRNA cancer vaccine inducing a persistent immune response in pancreatic cancer patients. Additionally, the company has secured $145 million in funding for African vaccine plants and plans to begin mRNA vaccine production in Rwanda by 2025. Despite these developments, the company's shares have been struggling, coming under the heat of the Inflation Reduction Act, and is also facing issues over default on royalty payments from the COVID-19 vaccine. With its share of ups and downs, BioNtech aims for a growth revival by 2025 and forecasts about 90% of 2024 revenues to materialize towards year-end.
BIONTECH News Analytics from Mon, 06 Nov 2023 08:00:00 GMT to Sat, 17 Aug 2024 10:37:47 GMT -
Rating -4
- Innovation 6
- Information 2
- Rumor -1
